Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men.

Editorial study summary

Study type

Human randomized trial

Product relevance

Secondary human context; read with the methodological caveat.

Sample or population

42 older men randomized; 22 participants’ 12-week data excluded after supplement-allocation error

Studied dose

NMN 250 mg/day

Duration

6 and 12 weeks

Finding

Blood NAD+ increased. Exploratory walking-speed and left-hand grip findings were nominally significant; body composition did not significantly change.

Limitations

A supplier allocation error substantially reduced the 12-week analysis. Exploratory multiple comparisons were not corrected. The mobility findings require confirmation.

Study quality

Full text and PubMed

Funding and disclosures

Funded by Mitsubishi Corporation Life Sciences, which supplied NMN; three authors were employees.

This research does not establish results for a DR.MORGAN finished product.

Reference

1. Igarashi M et al. · 2022 · PMID 35927255